Fri, Dec 26, 2014, 1:20 PM EST - U.S. Markets close in 2 hrs 40 mins

Recent

% | $
Quotes you view appear here for quick access.

Meridian Bioscience, Inc. Message Board

  • manilaasia manilaasia Sep 14, 2006 10:50 AM Flag

    This is the type of news we waited for!

    VIVO has had nothing but great press release. Addition to the S&P 600 will mean some big volume buys after 18 Sept. Earnings will be released in October as well as another dividend distribution. The fact that VIVO was taken into the S&P 600 SC is assures mme that VIVO will beat the estimates this quarter. I wish I bought more on the last dip. It'd be an added benifit if VIVO is reinducted into the IBD 100, which I think is highly likely. Appearently, there's been another strong buy recomendation. we should get a press release on that soon. I see VIVO at $30+ soon!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Manilaasia - Any word on when the new analyst will announce? That bit of info would definitely make it all look even better.

    • I hope you are right, but then again there are a few troubling little tidbits. I wonder how many companies can maintain the type of growth they have had.


      The recent merger with Merck is promising, but I wonder what the timeline is on that. VIVO isnt exactly tearing up the street lately releasing new products. Anyone know what they got in the pipeline. The insider trading right now is also highly suspicious. Lots of selling from VPs, not much buying...and right before the end of the fiscal year also. Can only speculate as to what they know, but me and my dollar would rather see buying or holding before the end of the fiscal year.

 
VIVO
16.76+0.08(+0.48%)1:14 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.